[1]李高勤,张志明,颉志英,等.基于WGCNA联合网络药理学探讨益髓生血胶囊治疗肝细胞癌的分子机制[J].西部中医药,2024,37(10):56-63.[doi:10.12174/j.issn.2096-9600.2024.10.14]
　LI Gaoqin,ZHANG Zhiming,JIE Zhiying,et al.Molecular Mechanism of Benefiting-marrow Generating-blood Capsules in the Treatment of Hepatocellular Carcinoma Based on WGCNA and Network Pharmacology[J].Western Journal of Traditional Chinese Medicine,2024,37(10):56-63.[doi:10.12174/j.issn.2096-9600.2024.10.14]
点击复制

基于WGCNA联合网络药理学探讨益髓生血胶囊治疗肝细胞癌的分子机制
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
37
期数:
2024年10期
页码:
56-63
栏目:
二次研究
出版日期:
2024-10-15

文章信息/Info

Title:
Molecular Mechanism of Benefiting-marrow Generating-blood Capsules in the Treatment of Hepatocellular Carcinoma Based on WGCNA and Network Pharmacology
作者:
李高勤1, 张志明2, 颉志英1, 苏欢1, 张欣1, 张卫强1, 黄达1, 李娟1, 雍文兴1
1.甘肃中医药大学附属医院，甘肃 兰州 730000
2.甘肃省中医院，甘肃 兰州 730050
Author(s):
LI Gaoqin1, ZHANG Zhiming2, JIE Zhiying1, SU Huan1, ZHANG Xin1, ZHANG Weiqiang1, HUANG Da1, LI Juan1, YONG Wenxing1
1.Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou 730000, China
2.Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, China
关键词:
肝细胞癌; 网络药理学; WGCNA; 益髓生血胶囊
Keywords:
hepatocellular carcinoma; network pharmacology; WGCNA; benefiting-marrow generating-blood capsules
分类号:
R285
DOI:
10.12174/j.issn.2096-9600.2024.10.14
文献标志码:
A
摘要:
目的基于加权基因共表达网络分析（weighted gene co-expression network analysis，WGCNA）联合网络药理学方法探讨益髓生血胶囊治疗肝细胞癌（hepatocellular carcinoma，HCC）的分子机制，筛选肝细胞癌潜在预后标志物。 方法采用中药系统药理学数据库与分析平台（traditional Chinese medicine systems pharmacology database and analysis platform，TCMSP）筛选益髓生血胶囊有效成分对应靶点；从TCGA数据库下载HCC及癌旁组织基因芯片，通过“Limma”包筛选差异基因；使用WGCNA包通过TCGA数据库中HCC的基因表达数据图谱构建基因共表达网络，筛选与临床性状相关基因模块；对益髓生血胶囊调控基因、HCC差异基因、模块基因取交集；使用Cytoscape构建药物-靶点-疾病网络，对交集基因进行基因本体论（gene ontology，GO）和京都基因与基因组百科全书（kyoto encyclopedia of genes and genomes，KEGG）通路富集分析；使用STRING数据库构建交集基因间的蛋白-蛋白互作（protein-protein interactions，PPI）网络；根据最大团中心性（maximal clique centrality，MCC）评分对前10个基因与HCC的预后进行探索，进一步分析以获得HCC潜在标志物。 结果共获得益髓生血胶囊438个有效成分对应靶点；从TCGA数据库共获得374个肿瘤样本和50个正常样本，Limma包共筛选出2703个差异基因；WGCNA筛选出1922个与正常组织相关的基因，交集基因共26个，主要富集于细胞衰老、细胞周期、乙肝、p53信号通路、多种癌症、IL-17等信号通路；26个交集基因中，7个基因的高表达与肝癌患者的较差总生存率（overall survival，OS）/无病生存率（disease free survival，DFS）具有显著差异（P＜0.05）。 结论益髓生血胶囊治疗HCC的作用机制复杂，主要涉及细胞衰老、细胞周期、乙肝、p53信号通路、多种癌症、IL-17等信号通路，其主要作用成分可能与槲皮素、木樨草素、芦荟大黄素、芒柄花素等有关。BIRC5、CCNA2、CCNB1、CDK1、CHEK1、E2F1、TOP2A等7个基因可能为HCC的潜在预后生物标志物。
Abstract:
ObjectiveTo discuss molecular mechanism of Yisui Shengxue (Benefiting-marrow Generating-blood) capsules in the treatment of hepatocellular carcinoma on the foundation of weighted gene co-expression network analysis (WGCNA) and network pharmacology, and to screen for potential prognostic markers in hepatocellular carcinoma. MethodsTCMSP was adopted to screen the corresponding targets of the active ingre-dients of the capsules; the gene chips of hepatocellular carcinoma and paraneoplastic tissue were downloaded from TCGA database, and the differential genes were screened from Limma package; the WGCNA package was used to construct the gene co-expression network for the gene expression data map of hepatocellular carcinoma in TCGA database, and screen the gene modules related to clinical traits; the intersection of benefiting-marrow generating-blood capsules regulatory genes, hepatocellular carcinoma differential genes and module genes were taken to construct the internet of drug-target-disease by Cytoscape, GO and KEGG pathway enrichment analysis of the intersected genes were conducted; STRING database was adopted to construct protein-protein interactions (PPI) network; the top ten genes and the prognosis of hepatocellular carcinoma were surveyed according to maximal clique centrality (MCC) scales, in order to obtain the potential markers of hepatocellular carcinoma by further analysis. ResultsThe analysis has yielded 438 corresponding targets of active ingredients of the capsules; 374 tumor samples and 50 normal samples were obtained from TCGA database, and 2703 differential genes were gained from Limma package; 1922 genes related to normal tissues and 26 intersected genes were screened by WGCNA, mainly concentrated in cell senescence, cell cycle, hepatitis B, p53 signaling pathway, many kinds of cancer, IL-17 and other signling pathways; among the 26 intersection genes, the significant differences existed between the high expression of seven genes and the poor overall survival (OS)/disease free survival (DFS) in patients with liver cancer (P<0.05). ConclusionThe complex mechanism of the capsules in the treatment of hepatocellular carcinoma mainly involves cellular aging, cell cycle, hepatitis B, p53 signaling pathway, many kinds of cancer, IL-17 and other signling pathways, and its main active ingredients are likely to related to quercetin, luteolin, aloe emodin and formononetin. Seven genes including BIRC5, CCNA2, CCNB1, CDK1, CHEK1, E2F1 and TOP2A may be the potential prognostic biomarkers of hepatocellular carcinoma.

相似文献/References:

[1]卢冠铭,黄照权,梁烨,等.中药对改善介入治疗肝癌患者凝血纤溶功能紊乱情况的研究[J].西部中医药,2013,26(07):1.
　LU Guanming,HUANG Zhaoquan,LIANG Ye,et al.Study on TCM Improving Cruor-fibrinolysis Disorders of Liver Cancer Patients Given with Interventional Therapy[J].Western Journal of Traditional Chinese Medicine,2013,26(10):1.
[2]田琳,毕胜男,陈梦竹,等.基于网络药理学探索血府逐瘀汤治疗非小细胞肺癌的作用机制[J].西部中医药,2022,35(01):21.[doi:10.12174/j.issn.2096-9600.2022.01.05]
　TIAN Lin,BI Shengnan,CHEN Mengzhu,et al.Research on the Mechanism of Xuefu Zhuyu Decoction in the Treatment of NSCLC Based on Network Pharmacology[J].Western Journal of Traditional Chinese Medicine,2022,35(10):21.[doi:10.12174/j.issn.2096-9600.2022.01.05]
[3]吴春凤,黄艳霞,郑景辉.基于网络药理学分析荆芥—防风药对的分子作用机制[J].西部中医药,2022,35(02):74.[doi:10.12174/j.issn.2096-9600.2022.02.18]
　WU Chunfeng,HUANG Yanxia,ZHENG Jinghui.Molecular Mechanism of Couplet Medicinals Jingjie‐Fangfeng Based on Network Pharmacology[J].Western Journal of Traditional Chinese Medicine,2022,35(10):74.[doi:10.12174/j.issn.2096-9600.2022.02.18]
[4]陶鑫,薛中峰,覃骊兰.基于网络药理学的过敏煎治疗过敏性哮喘分子机制研究[J].西部中医药,2022,35(03):27.[doi:10.12174/j.issn.2096-9600.2022.03.07]
　TAO Xin,XUE Zhongfeng,QIN Lilan.Study on the Molecular Mechanism of Guomin Jian in the Treatment of Allergic Asthma Based on Network Pharmacology[J].Western Journal of Traditional Chinese Medicine,2022,35(10):27.[doi:10.12174/j.issn.2096-9600.2022.03.07]
[5]黄康勤.基于网络药理学预测穿心莲内酯抗呼吸道感染的分子作用机制[J].西部中医药,2022,35(03):33.[doi:10.12174/j.issn.2096-9600.2022.03.08]
　HUANG Kangqin.Molecular Mechanism of Andrographolide against Respiratory Tract Infection Predicted by Network Pharmacology[J].Western Journal of Traditional Chinese Medicine,2022,35(10):33.[doi:10.12174/j.issn.2096-9600.2022.03.08]
[6]石威,张俊忠,解鹏超,等.基于网络药理学和分子对接探析淫羊藿-牛膝药对治疗股骨头坏死的作用机制[J].西部中医药,2022,35(04):35.[doi:10.12174/j.issn.2096-9600.2022.04.09]
　SHI Wei,ZHANG Junzhong,XIE Pengchao,et al.Study on the Mechanism of Yinyanghuo-Niuxi Drug Pair in Treating Femoral Head Necrosis Based on Network Pharmacology and Molecular Docking[J].Western Journal of Traditional Chinese Medicine,2022,35(10):35.[doi:10.12174/j.issn.2096-9600.2022.04.09]
[7]刘卓超,黄小靖,曾志聪.黄连生物碱改善心力衰竭的网络药理学机制研究[J].西部中医药,2022,35(04):42.[doi:10.12174/j.issn.2096-9600.2022.04.10]
　LIU Zhuochao,HUANG Xiaojing,ZENG Zhicong.Study on the Mechanism of Coptis Alkaloid in the Treatment of Heart Failure Based on Network Pharmacology[J].Western Journal of Traditional Chinese Medicine,2022,35(10):42.[doi:10.12174/j.issn.2096-9600.2022.04.10]
[8]张维芯,周青,戴国梁,等.基于SARS-CoV-2关键蛋白ACE2探索“葛根-柴胡”治疗COVID-19的潜在机制[J].西部中医药,2022,35(05):1.[doi:10.12174/j.issn.2096-9600.2022.05.01]
　ZHANG Weixin,ZHOU Qing,DAI Guoliang,et al.The Potential Mechanism of “Gegen-Chaihu” in the Treatment of COVID-19 Based on SARS-CoV-2 Target Protein ACE2[J].Western Journal of Traditional Chinese Medicine,2022,35(10):1.[doi:10.12174/j.issn.2096-9600.2022.05.01]
[9]林鑫,刘阳,陈林伟,等.基于网络药理学探讨气血双补方抗慢性心力衰竭的作用机制[J].西部中医药,2022,35(06):29.[doi:10.12174/j.issn.2096-9600.2022.06.08]
　LIN Xin,LIU Yang,CHEN Linwei,et al.Study on the Mechanism of Qixue Shuangbu Prescription in Treating Chronic Heart Failure Based on Network Pharmacology[J].Western Journal of Traditional Chinese Medicine,2022,35(10):29.[doi:10.12174/j.issn.2096-9600.2022.06.08]
[10]潘威.基于网络药理学探讨大黄治疗溃疡性结肠炎的机制[J].西部中医药,2022,35(06):80.[doi:10.12174/j.issn.2096-9600.2022.06.21]
　PAN Wei.The Mechanism of Dahuang in Treating Ulcerative Colitis Based on Network Pharmacology[J].Western Journal of Traditional Chinese Medicine,2022,35(10):80.[doi:10.12174/j.issn.2096-9600.2022.06.21]

备注/Memo

备注/Memo:
李高勤（1995—），男，硕士学位，主治医师。研究方向：急危重症医学。国家自然科学基金地区基金（81660730）；甘肃省中西医结合肿瘤临床医学研究中心项目（18JR2FA001）。
更新日期/Last Update: 2024-10-15